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Bone marrow ﬁbrosis has been associated with different types of non-neoplastic conditions like gran-
ulomatous and autoimmune diseases and a variety of neoplastic disorders such as acute mega-
karyoblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma and myeloproliferative neoplsms.
Therapy induced ﬁbrosis is a rare phenomenon. Here we report a case of an incidentally diagnosed acute
promyelocytic leukemia (APL) with t(11;17) which was treated with arsenic trioxide (ATO) for 45 days.
However, the patient did not go into remission and developed massive ﬁbrosis of bone marrow. Lit-
erature search does not reveal such documented marrow ﬁbrosis following therapy with ATO in a case of
APL.
& 2015 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Bone marrow ﬁbrosis is known to occur in several neoplastic
and non-neoplastic conditions. Among neoplastic conditions such
as acute leukemia, it is most often seen with acute mega-
karyoblastic leukemia [1]. Acute promyelocytic leukemia (APL)
presenting with marrow ﬁbrosis is a rare entity, with few cases
reported in the past [2–4]. In one case series a reversible bone
marrow collagenous ﬁbrosis has been reported in cases of APL
treated with tretinoin [5]. However literature search did not reveal
any such occurrence of bone marrow ﬁbrosis following therapy
with arsenic trioxide (ATO) in a case of APL. Here we report a case
of 44 year old female who was diagnosed as APL with t(11;17),
who subsequently developed bone marrow collagenous ﬁbrosis
following induction therapy with ATO.Case history
A 44 year old female, known hypothyroid and hypertensive onn open access article under the C
Venkatesan),
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.com (R. Kumar),
ti@yahoo.com (H.P. Pati),regular medication, presented with spontaneous skin bleed for
ﬁve months, generalized weakness, fatigability and menorrhagia
for three months duration. She was diagnosed to have ﬁbroid
uterus and underwent diagnostic dilatation and curettage (D&C)
for her complaints at an outside hospital. As her bleeding per
vaginum did not stop after D&C, hysterectomy was performed.
During the post operative period she was found to have high total
leukocyte count (TLC). Subsequently the patient developed pain
abdomen, found to have hemoperitoneum and exploratory lapar-
otomy was carried out to achieve hemostasis. Since she had high
TLC, bone marrow examination and cytogenetics were carried out
which revealed abnormal promyelocytes and 45X, X, t(11;17)
(q23;q21) respectively (Fig. 1). Based on the morphological and
cytogenetic abnormality, diagnosis of APL was made and the pa-
tient was transferred to our center for further management. On
examination she had pallor, fever, multiple purpuric spots over
upper and lower limbs, a midline abdominal suture wound with
gaping and necrotic slough along with foul smelling discharge.
Respiratory system examination revealed diminished breath
sounds in left infrascapular region suggestive of pleural effusion.
CT scan chest showed bilateral ground glass opacities suggestive of
fungal pneumonia and left sided pleural effusion. There was no
organomegaly or peripheral lymphadenopathy. Laboratory para-
meters revealed hemoglobin of 69 g/L, TLC of 35.39109/L with a
differential leukocyte count of 50% promyelocytes, 19% myelocytes,
01% metamyelocyte, 27% mature neutrophils, 03% lymphocytes
and platelet count of 44109/L. After admission to our center, herC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Bone marrow aspirate – blast, promyelocyte along with mature myeloid cells (A, Jenner Giemsa stain, 1000). Bone marrow biopsy showing diffuse replacement by
immature myeloid cells with no ﬁbrosis. (B, Hematoxylin & Eosin stain, 400). Bone marrow aspirate – strong MPO positivity (C, myeloperoxidase stain, 1000). Kar-
yogram showing 45X, X, t(11;17)(q23;q21) (D, karyotype).
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was no laboratory evidence of disseminated intravascular coagu-
lation. Bone marrow examination revealed 45% hypergranular
promyelocytes with 03% blasts, 40% maturing myeloid forms and
neutrophils, 06% erythroid cells and 06% lymphocytes. There were
no Auer rods or fagot cells seen. Myeloperoxidase stain showed
strong MPO positivity in these promyelocytes. The bone marrow
biopsy showed near total replacement by immature myeloid forms
without marrow ﬁbrosis (Fig. 1). In view of foci of infections in-
volving lung and gaping infected wound in anterior abdominal
wall, patient was not offered Inj daunorubicin and all trans retinoic
acid. Instead she was started on ATO at a dose of 0.15 mg/kg body
weight along with supportive antibiotics and antifungals. During
therapy she became afebrile, her abdominal wound healed and
lung lesions resolved. The TLC reduced gradually along with signs
of maturation in the peripheral smear. However by dayþ45, pa-
tient developed pancytopenia and hence bone marrow examina-
tion was performed to assess the disease status. Bone marrow
aspiration yielded a dry tap and the bone marrow biopsy tissue
obtained was pale and gray white on gross examination. The
peripheral smear received along with the bone marrow revealed
an occasional promyelocyte and the bone marrow aspirate smears
were paucicellular which revealed 03% blasts, 08% promyelocytes,
11% myelocytes, 07% metamyelocytes, 10% neutrophils and 61%
lymphocytes. The bone marrow biopsy tissue revealed dense dif-
fuse marrow ﬁbrosis with extensive collagen deposition suggestive
of grade III marrow ﬁbrosis [6] conﬁrmed on Masson trichrome
stain, with entrapped immature myeloid forms of similar mor-
phology observed in the diagnostic marrow (Fig. 2). The therapy
with ATO was discontinued in view of bone marrow ﬁbrosis and
patient was observed with supportive care. Subsequently, on fol-
low up the TLC and promyelocyte count in peripheral smear in-
creased in number. As the patient did not have any foci of infec-
tion, she is now started on induction chemotherapy withdaunorubicin and all-trans retinoic acid.Discussion
Bone marrow ﬁbrosis is known to be associated with hemato-
lymphoid malignancies such as acute leukemia, Hodgkin and non-
Hodgkin lymphoma. Among the acute leukemias, marrow ﬁbrosis
is most often seen with acute megakaryoblastic leukemia. It is an
uncommon ﬁnding in APL and till date only handful of case reports
are seen in literature, however its presence does not seem to alter
the prognosis of APL [4,7]. Hatake et al. demonstrated bone mar-
row ﬁbrosis following therapy with tretinoin and also proved that
the ﬁbrosis is reversible after stopping tretinoin and chemother-
apy [5]. However there is no reports so far mentioned in literature
regarding marrow ﬁbrosis post ATO therapy, hence our case would
be the ﬁrst of its kind with this unique ﬁnding. In APL ATO has
dose dependant effect on promyelocytes inducing preferential
apoptosis at high concentration (0.5–2 μmol/L), inducing partial
differentiation at low concentration (0.1–0.5 μmol/L) and causing
modulation and degradation of PML-RARα protein at a dose of
0.1–0.2 μmol/L [8]. Mori et al. suggested a possible role of trans-
forming growth factor beta (1) (TGF-β1) in causing the ﬁbrosis in
APL as they have noticed the overexpression of TGF-β1 by RT-PCR
[2]. A similar mechanism is possible with ATO in inducing bone
marrow ﬁbrosis as brought out by Chu et al. who had established
the role of ATO-induced TGF-β1secretion from cardiac ﬁbroblasts
which resulted in myocardial ﬁbrosis [9]. In the same line Szy-
mańska-Chabowska et al. demonstrated the role of arsenic in liver
ﬁbrosis leading to chronic hepatic failure [10]. Hence it can be said
with reasonable conﬁdence that, as ATO is capable of inducing
ﬁbrosis in heart and liver, it is possible for ATO to induce bone
marrow ﬁbrosis as well even though it is not mentioned in lit-
erature so far. Whether this ATO induced ﬁbrosis in unique to the
Fig. 2. Bone marrow biopsy showing diffuse ﬁbrosis with collagenisation along with entrapped immature myeloid cells (A – Hematoxylin & Eosin stain, 100, B – He-
matoxylin & Eosin stain, 400, C – reticulin stain, 100, and D – Masson trichrome stain, 400).
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Also the outcome of this marrow ﬁbrosis needs to be ascertained
from further follow up of this patient. As RT-PCR for PML-RARα
will not help in this case to assess the molecular remission, the
patient needs to be followed up with conventional cytogenetics or
FISH analysis for molecular remission status. This case had so
many unusual features such as a long duration of illness, un-
common morphological ﬁndings, rare cytogenetic abnormality
and ATO induced bone marrow ﬁbrosis. Hence the case is reported
for this constellation of unique features.Source of support
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